Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safety Data Need Not Be Significant To Prompt Action, FDA’s Graham Says

Executive Summary

FDA should be less concerned with statistical significance in evaluating potential safety issues, Office of Drug Safety Associate Director for Science David Graham said Aug. 23

You may also be interested in...



Daytrana Safety Issues Remain, Concern Lessened, Reviewer Says In Reversal

Safety issues with Shire/Noven's Daytrana methylphenidate patch remain but the agency's concern about them has been lessened, FDA's clinical reviewer said in a reversal of his written evaluation on the approvability of the attention deficit/hyperactivity disorder product

Daytrana Safety Issues Remain, Concern Lessened, Reviewer Says In Reversal

Safety issues with Shire/Noven's Daytrana methylphenidate patch remain but the agency's concern about them has been lessened, FDA's clinical reviewer said in a reversal of his written evaluation on the approvability of the attention deficit/hyperactivity disorder product

Merck After Vioxx: No Merger, But No Big Near-Term Launches

Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed

Related Content

Topics

UsernamePublicRestriction

Register

PS046288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel